@article {957, title = {Perceived quality of life (QOLIE-31-P), depression (NDDI-E), anxiety (GAD-7), and insomnia in patients with epilepsy attended at a refractory epilepsy unit in real-life clinical practice}, journal = {Neurological Sciences}, volume = {43}, year = {2022}, month = {2022}, pages = {1955-1964}, doi = {https://doi.org/10.1007/s10072-021-05595-3}, url = {https://link.springer.com/article/10.1007/s10072-021-05595-3}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and Vieira Campos, Alba and Mart{\'\i}nez-Dubarbie, Francisco and Vivancos, Jos{\'e} and De Toledo-Heras, Mar{\'\i}a} } @article {943, title = {Medium-term changes in patients with epilepsy during the COVID-19 pandemic}, journal = {Acta Neurologica Scandinavica}, volume = {144}, year = {2021}, pages = {450-459}, abstract = {

Objectives: The novel coronavirus disease (COVID-19) pandemic has led to social distancing measures and impaired medical care of chronic neurological diseases, including epilepsy, which may have adversely affected well-being and quality of life of patients with epilepsy (PWE). The objective of this study is to evaluate the impact of the COVID-19 pandemic in the levels of anxiety, depression, somnolence, and quality of life using validated scales in PWE in real-life clinical practice.

Materials \& Methods: Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale; ESS), and quality of life (QOLIE-31-P) in PWE treated in a Refractory Epilepsy Unit were longitudinally analyzed. Data were collected before the beginning (December 2019-March 2020) and during the COVID-19 pandemic (September 2020-January 2021).

Results: 158 patients (85 from the first round and 73 from the second round) 45.0 +- 17.3 years of age, 43.2\% women, epilepsy duration 23.0 +- 14.9 years, number of antiepileptic drugs 2.1 +- 1.4, completed the survey. Significant longitudinal reduction of QOLIE-31-P (from 58.9 +- 19.7 to 56.2 +- 16.2, p = 0.035) and GAD-7 scores (from 8.8 +- 6.2 to 8.3 +- 5.9, corrected p = .024) was identified. No statistically significant longitudinal changes in the number of seizures (from 0.9 +- 1.9 to 2.5 +- 6.2, p = .125) or NDDI-E scores (from 12.3 +- 4.3 to 13.4 +- 4.4, p = .065) were found. Significant longitudinal increase of ESS (from 4.9 +- 3.7 to 7.4 +- 4.9, p = .001) was found.

Conclusions: During the COVID-19 pandemic, quality of life and anxiety levels were lower in PWE, and sleepiness levels were raised, without seizure change.

}, keywords = {Anxiety, COVID-19, Sleep, epilepsy, pandemic, quality of life}, doi = {https://doi.org/10.1111/ane.13481}, url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/ane.13481}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and Vieira Campos, Alba and Mart{\'\i}nez-Dubarbie, Francisco and Vivancos, Jos{\'e} and De Toledo-Heras, Mar{\'\i}a} } @conference {917, title = {The utility of the GAD-7 anxiety, NDDI-E depression, Epworth sleepiness and QOLIE-31-P quality of life scales in patients with epilepsy in real clinical practice (2379)}, booktitle = {Proceedings of the American Academy of Neurology 2021 Virtual Annual Meeting}, year = {2021}, publisher = {Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology}, organization = {Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology}, abstract = {

Objective: The objective of this project is to study the presence of psychiatric comorbidity (anxiety and depression), somnolence and quality of life using validated scales in patients with epilepsy in real clinical practice, and its relationship with other clinical and demographic variables.

Background: Previous studies have shown that psychiatric comorbidity, specially anxiety and depression, as well as sleep disorders are more prevalent in patients with epilepsy than in the general population.

Design/Methods: Cross-sectional descriptive observational study using validated scales of anxiety disorders(GAD-7), depression(NDDI-E), sleep disorders(Epworth) and quality of life(QOLIE-31-P) in patients with epilepsy treated in the Refractory Epilepsy Unit of a tertiary hospital.

Results: We recruited 84 patients, age 44.3 {\textpm} 17.4 years, 48.2\% women, duration of epilepsy 21.5 {\textpm} 15.9 years, number of antiepileptic drugs 1.9 {\textpm} 1.2. We found severe anxiety(GAD-7\> 14) in 14.3\%, depression(NDDI-E\> 15) in 20.2\%; abnormal sleepiness(Epworth\> 10) in 14.3\% of patients, and QOLIE-31-P 62.0 {\textpm} 19.2. Each more point in GAD-7 is 21\% more likely to suffer from anxiety(OR 1.21; 95\% CI 1.09{\textendash}1.36; p = 0.0008), NDDI-E scores\<=15 represent 85 \% less chance of having depression(OR 0.15; 95\% CI 0.04{\textendash}0.51]; p = 0.002). We found a positive association between depression according to NDDI-E with seizure frequency(p = 0.017) and number of drugs(p = 0.019); and severe anxiety according to GAD-7 and number of drugs(p = 0.019). We found a negative correlation between QOLIE-31-P with NDDI-E(r = -0.68; p \<0.0001) and GAD-7(r = -0.76; p \<0.0001).

Conclusions: Validated scales in epilepsy for the detection of anxiety(GAD-7) and depression(NDDI-E) are useful in the detection of these disorders in real clinical practice. The assessment of the presence of anxiety-depressive psychiatric comorbidity is especially relevant in patients with a higher frequency of seizures, a greater number of drugs and a poorer quality of life.

}, url = {https://n.neurology.org/content/96/15_Supplement/2379}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and Mart{\'\i}nez-Dubarbie, Francisco and Vieira Campos, Alba and Vivancos, Jos{\'e} and De Toledo, Mar{\'\i}a} }